Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis
Both biologics are effective for CRSwNP, but their efficacy profiles differ. Dupilumab provides faster olfactory and nasal polyp improvements. Personalized biologic selection is essential, and further studies are needed to define long-term outcomes.
Authors
- Sonny Zampollo
- Arabella Fontana
- Tommaso Saccardo (ORCID: https://orcid.org/0000-0002-8349-9569)
- Piero Nicolai (ORCID: https://orcid.org/0000-0003-0443-3519)
- Giancarlo Ottaviano (ORCID: https://orcid.org/0000-0003-2433-4761)
- Bruno Scarpa (ORCID: https://orcid.org/0000-0002-9628-5164)
- Nicola Tessari
- Giuseppe Roccuzzo (ORCID: https://orcid.org/0000-0001-6731-8054)
Institutions
- University of Padua (IT)
Publication Details
- Journal
- European Archives of Oto-Rhino-Laryngology
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1007/s00405-025-09725-x
- Citations
- 1
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.85